Brief: Skye Bioscience Surpasses 50% Patient Enrollment In Phase 2 Obesity Study Of Differentiated CB1 Inhibitor
14/11/2024 12:23
Nov 14 (Reuters) - Skye Bioscience Inc SKYE.O :
* SKYE BIOSCIENCE SURPASSES 50% PATIENT ENROLLMENT IN PHASE
2
OBESITY STUDY OF DIFFERENTIATED CB1 INHIBITOR
* SKYE BIOSCIENCE INC - EXPECTS INTERIM DATA FOR CBEYOND
PHASE 2
TRIAL IN Q2 2025
Source text: urn:newsml:reuters.com:*:nGNXbSSgY1
Further company coverage: SKYE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Skye Bioscience
See all newsBrief: Skye Announces Cohort Review Committee Approved Opening Of Cohort 2 Based On Favorable Safety Data From First Four Participants Treated In Cohort 1
U.S. RESEARCH ROUNDUP-Accuray, Aevex, Zoetis
U.S. STOCKS ON THE MOVE-Tesla, Blue Owl, Ford
U.S. STOCKS ON THE MOVE-Energy firms, Estee Lauder, HMH Holding
Skye Bioscience rises as it begins testing higher doses of obesity drug